PathMaker Neurosystems Announces Issuance of Three Patents Protecting the Use of Company’s Proprietary Neuromodulation Technology in ALS
BOSTON, March 05, 2025 (GLOBE NEWSWIRE) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), announced today the issuance of three recent patents covering the application of our Company’s proprietary neuromodulation technology to the treatment of ALS. The United States Patent and Trademark Office